PATENT CLAIM ANALYSIS

Application Number: 15985097
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "394000"]

Abstract:
The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.

Claim (Index 25):
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a combination according to  claim 1 .

Metadata:
- Claim Count in Document: 79.0
- Percentile: 93.0
- Lexical Diversity: 1.97619
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15314167', '13762238', '15277857', '13417185', '12721645']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6757108871393097
- 35 USC 102 Novelty (BERT): 0.5580500582024719
- Combined Prediction Score: 0.663944804245626
- Mean Citation Score: 309.09669
- Max Citation Score: 421.08868
- Similarity Product: 371.0370728750515

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test